

Supplemental Data

Table S1. Treatment Pattern of Patients With mCRPC Before mCRPC Diagnosis to Third-Line

Treatment for Total Population – Aggregated Data (n = 168)

Before mCRPC		First line, n (%)		Second line, n (%)		Third line, n (%)			
ADT only	86 (51.2)	ABI or ENZA	32 (37.3)	ABI or ENZA	2 (6.3)	LOSS	2 (100.0)		
				DOC	11 (34.3)	ABI or ENZA	3 (27.3)		
						CAB	2 (18.2)		
				LOSS	6 (54.5)				
				LOSS	19 (59.4)	LOSS	19 (100.0)		
		AA	23 (26.7)	ABI or ENZA	10 (43.5)	ABI or ENZA	1 (10)	DOC	2 (20.0)
						DOC	2 (20.0)	LOSS	7 (70.0)
						DOC	5 (21.7)	ABI or ENZA	2 (40.0)
								LOSS	3 (60.0)
						LOSS	6 (26.1)	LOSS	6 (100.0)
DOC	31 (36.0)	ABI or ENZA	12 (38.7)	Others	2 (8.7)	ABI or ENZA	1 (50.0)		
						DOC	1 (50.0)		
						ABI or ENZA	4 (33.3)		
				CAB	1 (8.3)				

						DOC	1 (8.3)
						LOSS	6 (50.0)
				AA	1 (3.2)	LOSS	1 (100.0)
				CAB	3 (9.7)	ABI or ENZA	2 (67.7)
						LOSS	1 (33.3)
				LOSS	15 (48.4)	LOSS	15 (100.0)
ADT + ABI	8 (4.8)	ABI or ENZA	3 (37.5)	ABI or ENZA	1 (33.3)	LOSS	1 (100.0)
				DOC	2 (66.7)	LOSS	2 (100.0)
		DOC	5 (62.5)	ABI or ENZA	1 (20.0)	CAB	1 (100.0%)
				CAB	2 (40.0)	LOSS	2 (100.0)
				LOSS	2 (20.0)	LOSS	2 (100.0)
ADT + AA	54 (32.2)	ABI or ENZA	28 (51.8)	ABI or ENZA	3 (10.7)	DOC	1 (33.3)
						LOSS	2 (66.7)
				DOC	14 (50.0)	ABI or ENZA	2 (14.3)
						CAB	3 (21.4)
						LOSS	9 (64.3)
				LOSS	11 (39.3)	LOSS	11 (100.0)
		AA	3 (5.6)	ABI or ENZA	2 (66.7)	DOC	1 (50.0)
						LOSS	1 (50.0)
				DOC	1 (33.3)	LOSS	1 (100.0)

		DOC	23 (42.6)	ABI or ENZA	13 (56.5)	ABI or ENZA	1 (7.7)
						CAB	3 (23.1)
						DOC	2 (15.4)
						LOSS	6 (46.2)
						Others	1 (7.7)
				CAB	5 (21.7)	ABI or ENZA	1 (20.0)
						LOSS	4 (80.0)
				LOSS	4 (17.4)	LOSS	4 (100.0)
				Others	1 (4.3)	Others	1 (100.0)
ADT + DOC	20 (11.9)	ABI or ENZA	15 (75.0)	ABI or ENZA	4 (26.7)	CAB	2 (50.0)
						LOSS	2 (50.0)
				CAB	2 (13.3)	ABI or ENZA	1 (50.0)
						LOSS	1 (50.0)
				DOC	5 (33.3)	CAB	1 (20.0)
						LOSS	3 (60.0)
						Others	1 (20.0)
				LOSS	4 (26.7)	LOSS	4 (100.0)
		AA	1 (5.0)	LOSS	1 (100.0)	LOSS	1 (100.0)
		CAB	3 (15.0)	LOSS	3 (100.0)	LOSS	3 (100.0)
		DOC	1 (5.0)	LOSS	1 (100.0)	LOSS	1 (100.0)

AA: first-generation anti-androgen (bicalutamide or flutamide); ABI: abiraterone; ADT: androgen deprivation therapy; CAB: cabazitaxel; DOC: docetaxel; ENZA: enzalutamide; LOSS: information lost in tracking; mCRPC: metastatic castration-resistant prostate cancer.